We are live on ! Find out more
TEVA icon

Teva Pharmaceuticals
TEVA

429 hedge funds and large institutions have $5.14B invested in Teva Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 124 increasing their positions, 142 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

6% less call options, than puts

Call options by funds: $296M | Put options by funds: $315M

3% less funds holding

Funds holding: 440 → 429 (-11)

2.99% less ownership

Funds ownership: 50.84% → 47.85% (-3%)

7% less capital invested

Capital invested by funds: $5.55B → $5.14B (-$411M)

13% less first-time investments, than exits

New positions opened: 35 | Existing positions closed: 40

13% less repeat investments, than reductions

Existing positions increased: 124 | Existing positions reduced: 142

Holders
429
Holders Change
-11
Holders Change %
-2.5%
% of All Funds
7.51%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
35
Increased
124
Reduced
142
Closed
40
Calls
$296M
Puts
$315M
Net Calls
-$18.9M
Net Calls Change
+$23.5M

Top Buyers

Rank Fund Capital Flow
1
MMH
Menora Mivtachim Holdings
Israel
+$30.1M
2
BMO
Beck Mack & Oliver
New York
+$27.3M
3
PF
Phoenix Financial
Israel
+$24.5M
4
Jane Street
Jane Street
New York
+$24.4M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$24.3M

Top Sellers

Rank Fund Capital Flow
1
Capital World Investors
Capital World Investors
California
-$404M
2
Capital Research Global Investors
Capital Research Global Investors
California
-$35.4M
3
Norges Bank
Norges Bank
Norway
-$21.9M
4
Citigroup
Citigroup
New York
-$17.5M
5
JP Morgan Chase
JP Morgan Chase
New York
-$12M
Name Holding Trade Value Shares
Change 		Change in
Stake
PCG
401
Private Capital Group
Connecticut
$1K -$5.86K -626 -90%
AWM
402
Accel Wealth Management
Iowa
$1K – – –
CC
403
Corsicana & Co
Texas
$1K – – –
CFO
404
CVA Family Office
Colorado
$1K – – –
EARNEST Partners
405
EARNEST Partners
Georgia
$1K – – –
EWM
406
Endurance Wealth Management
Rhode Island
$1K – – –
HFM
407
Hartford Financial Management
Connecticut
$1K – – –
HCP
408
Hexagon Capital Partners
Arkansas
$1K – – –
JCM
409
Jacobi Capital Management
Pennsylvania
$1K – – –
KFI
410
Key Financial Inc
Pennsylvania
$1K – – –
LWA
411
Lowe Wealth Advisors
Maryland
$1K – – –
MAM
412
McCarthy Asset Management
California
$1K – – –
WWM
413
Wolff Wiese Magana
California
$1K – – –
CB
414
Community Bank
New York
$1K +$936 +100 New
IHWM
415
Iron Horse Wealth Management
Iowa
$1K +$936 +100 New
FHA
416
First Horizon Advisors
Tennessee
$1K +$1.4K +149 +414%
ED
417
Exane Derivatives
France
$536 – – –
AP
418
Archon Partners
New Jersey
– -$6.28M -634,000 Closed
Qube Research & Technologies (QRT)
419
Qube Research & Technologies (QRT)
United Kingdom
– -$3.45M -348,175 Closed
E
420
Ergoteles
New York
– -$2M -201,589 Closed
TI
421
Trexquant Investment
Connecticut
– -$1.35M -136,109 Closed
QC
422
Quadrature Capital
United Kingdom
– -$982K -99,112 Closed
SFA
423
Souders Financial Advisors
Ohio
– -$830K -83,821 Closed
BAM
424
Blueshift Asset Management
New Jersey
– -$663K -66,936 Closed
ECM
425
ExodusPoint Capital Management
New York
– -$521K -52,641 Closed
15 16
17
18 19

TEVA Hedge Fund Activity: Q3 2021 in Review

429 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q3 2021, worth a combined $5.14B — down 7.4% from $5.55B a quarter earlier.

Sellers outnumbered buyers: 40 funds closed out of TEVA and 35 opened new positions — a net loss of 5 holders — while 142 trimmed existing stakes and 124 added.

The largest buyer was Menora Mivtachim Holdings, adding an estimated $30.1M. The largest seller was Capital World Investors, cutting an estimated $404M.

  • 429 institutional investors held Teva Pharmaceuticals (TEVA) as of Q3 2021, down from 440 in Q2 2021.
  • Funds reported $5.14B of Teva Pharmaceuticals stock for Q3 2021, down 7.4% quarter-over-quarter.
  • 35 funds opened new Teva Pharmaceuticals positions in Q3 2021 and 40 closed out, a net change of -5 holders.
  • The largest Teva Pharmaceuticals buyer in Q3 2021 was Menora Mivtachim Holdings, an estimated $30.1M added.
  • The largest Teva Pharmaceuticals seller in Q3 2021 was Capital World Investors, an estimated $404M sold.

Based on aggregated 13F filings for Q3 2021.